bcrx stock forecast

sentiment. Get daily stock ideas top-performing Wall Street analysts. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. RBC Capital. High institutional ownership can be a signal of strong market trust in this company. All times are ET. All All Strong Buy Buy Hold Sell Strong Sell. Three analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. Trend. Twitter. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. Identify stocks that meet your criteria using seven unique stock screeners. Investors can use this forecasting interface to forecast Biocryst Pharma historical stock prices and determine the direction of Biocryst Pharma's future trends based on various well-known forecasting models. Related Link: Are Americans Ready To Travel? View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks. Evercore ISI Group. See what's happening in the market right now with MarketBeat's real-time news feed. Facebook. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BCRX Only Stock to Own. Consensus. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $11.78 in the next year. Bullish. Bullish. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. BCRX Stock Predictions. The BioCryst stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, ... BCRX Analyst Forecast > Blogger Opinions. Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) stock? However, many stock price predictions are published every day by banks, financial institutions and independent analysts. MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. BCRX stock forecast. You can opt out at any time. Fundamental company data provided by Zacks Investment Research. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. Buy: Initiates Coverage On: $12.00-0.58%: 2020-11-24: Anonymous. BCRX, 1D. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. The average price target is $9.07, with a high forecast of $13.00 and a low forecast of $4.50. View all of BCRX's competitors. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, UBS Asset Management Americas Inc., Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, and Edge Wealth Management LLC. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. 52 Week Low  $1.58. Miguel Garrison - January 11, 2021. BioCryst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. The trading price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) floating lower at last check on Monday, Jan 11, closing at $7.74, -3.26% lower than its previous close. Barclays. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information. Looking for new stock ideas? N/A. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. Export data to Excel for your own analysis. Post-Market 0.09 (0.69%) Compare Top Brokerages Here. View insider buying and selling activity for BioCryst Pharmaceuticals or view top insider-selling stocks. The biotechnology company had revenue of $4.02 million for the quarter, compared to analyst estimates of $14.72 million. The average price target is $9.86, with a high forecast of $14.00 and a low forecast of $6.00. BioCryst Pharmaceuticals, Inc. (BCRX) projections and forecasts. Get short term trading ideas from the MarketBeat Idea Engine. BCRX Only Stock to Own. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Stop-loss: $12.32 (-5.29%) Price … All rights reserved. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. The lowest EPS estimate is ($0.31) and the highest is ($0.23). BioCryst stock forecast & analyst price target predictions based on 10 analysts offering 12-months price targets for BCRX in the last 3 months. The stock broke below $10 for the first time on March 18 and ultimately bottomed at $7.80 in early April. To see how BioCryst Pharmaceuticals, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: BCRX stock’s performance was -3.26% at last check in today’s session, and +133.84% in the past year, while Zoetis Inc Cl A (ZTS) has been trading +0.87% in recent session and positioned +24.47% higher than it was a year ago. 11 brokers have issued 12-month price targets for BioCryst Pharmaceuticals' shares. Learn more. View which stocks have been most impacted by COVID-19. Investors will be thrilled if BCRX’s share price rises to $14, which is the median consensus price. View analysts' price targets for BioCryst Pharmaceuticals or view top-rated stocks among Wall Street analysts. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 Should I buy or sell BCRX stock? ... BCRX Stock Predictions, Articles, and Biocryst Pharma Inc News. Access to Intraday penny stock screener Scan for strong stocks Never miss a profitable trade. © 2020 Cable News Network. Trading Signals: BCRX Stock Price Prediction and Forecast (Tue. bcrx stock forecast for the next 10 days by pretiming ... Stock market timing forecast for the next 10 days, 10 weeks. By. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 100% FREE. High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years. Should I buy or sell BCRX? BCRX. BCRX -- USA Stock : USD 10.90 0.02 0.18% : Biocryst Pharma Stock Forecast is based on your current time horizon. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. BCRX Stock Predictions BCRX Stock Predictions. BCRX Stock Trend. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. BCRX Stock Forecast - Is BCRX a buy or sell? BCRX Related ETF s. Symbol %Holdings 3M %Chg; BCRX +55.67% : Biocryst Pharma Inc: XBI : 1.36% +2.98% : S&P Biotech SPDR: IWM : 0.08% +22.75% : Russell 2000 Ishares ETF: IBB : 0.19% +3.04% : Nasdaq Biotechnology Ishares ETF: IWO : 0.13% +15.30% : Russell 2000 Growth Ishares ETF: VTI : 0% +9.05% : Total Stock Market ETF Vanguard: Symbol %Holdings 3M %Chg; BCRX … The consensus among Wall Street research analysts is that investors should "buy" BioCryst Pharmaceuticals stock. BCRX Analyst Forecast > Blogger Opinions. BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. BioCryst Pharmaceuticals closed on Monday at $11.10 after barely changing a -0.45%. Forecast Earnings Dividend Ownership $12.64-0.35 (-2.69 %) Updated Mar 12, 2021. P/S  69.96x. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Do Not Sell My Information. View analyst ratings for BioCryst Pharmaceuticals or view top-rated stocks. BioCryst Pharmaceuticals, Inc. NASDAQ Updated Mar 16, 2021 11:59 PM BCRX 13.01 0.47 (3.49%). BCRX stock forecasts by analyst. No recent news for BioCryst Pharmaceuticals Inc. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. 12, 2021) (BioCryst Pharmaceuticals, Inc.) BCRX latest price $12.6150 (-2.4%) ($12.6150 - $12.6150) on Fri. Mar. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. If you are thinking about buying BCRX, make sure you check out the free BCRX stock prediction report provided by MarketClub.They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how BCRX will perform in the near future. The current price is about -34.31% off the estimated low and 16.79% off the forecast high, based on this estimate. There are currently 3 hold ratings and 8 buy ratings for the stock. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. Should I buy or sell BCRX stock? BCRX -- USA Stock : USD 9.79 0.14 1.45% : BioCryst Pharmaceuticals Stock Forecast is based on your current time horizon. BioCryst Pharmaceuticals made public its earnings report on February 25 ; BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock. Twitter. All Rights Reserved. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). BCRX Stock Forecast - Get a free BCRX stock predictions and find out whether you should buy or sell BCRX stock. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. BCRX forecasts Videos only. All Strong Buy Buy Hold Sell Strong Sell. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Limited Time Only. Should I buy or sell BCRX? Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 01:00 AM ET +0.96 (18.68%) … Analysts tracking BCRX have forecast the quarterly EPS to grow by -$0.28 per share this quarter, while the same analysts predict the annual EPS to hit -$1.05 for the year 2021 and up to -$0.73 for 2022. The trend analysis tool will help you make a better prediction on the BCRX stock. BioCryst Pharmaceuticals does not have a long track record of dividend growth. The average price target represents a 48.71% upside from the last price of $6.10. By. BioCryst Pharmaceuticals, Inc. share prices are not performing particularly well compared to other companies … Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$ . Long since 1.90's. Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. Tue, Mar 16, 2021 Buy Candidate Unchanged Analyst Ratings Last 30 days. BioCryst Pharmaceuticals has received 51.72% “outperform” votes from our community. In this case, analysts estimate an annual EPS growth of -0.04% for the year and -0.3% for the next year. Analyst / Firm Rating Action Price Target Upside/Downside Date; Gena Wang. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock … One share of BCRX stock can currently be purchased for approximately $13.24. The P/E ratio of BioCryst Pharmaceuticals is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. © American Consumer News, LLC dba MarketBeat® 2010-2021. Increased. Chart is setting up perfectly for 3/22 Data readout. BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. Earnings for BioCryst Pharmaceuticals are expected to decrease in the coming year, from ($0.96) to ($0.97) per share. Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. BCRX Blogger Predictions > Hedge Fund Activity . Their average twelve-month price target is $11.78, predicting that the stock has a possible downside of 11.04%. Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years. Never miss a profitable trade. The average price target represents a 3.00% upside from the last price of $9.57. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. BioCryst Pharmaceuticals has received a consensus rating of Buy. Long. 3M +48.71% 1W +13.36% 1M +32.08% 3M +48.71% 1Y +525.74% All. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings. 209 institutions hold shares in BioCryst Pharmaceuticals Inc. (BCRX), with 1.51M shares held by insiders accounting for 0.85% while institutional investors hold 74.58% of the company’s shares. Revenue vs Market: BCRX's revenue (42.4% per year) is forecast to grow faster than the US market (10.1% per year). Most stock quote data provided by BATS. BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. 0. Watchlist. BCRX Sentiment 100% Sector Average 70%. st0nkz Last visit Follow Following Unfollow. BioCryst Pharmaceuticals, Inc. (BCRX) stock is higher by 7.97% while the S&P 500 has fallen -0.65% as of 1:16 PM on Friday, Dec 11. Price target in 14 days: 14.810 USD. View BCRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. BioCryst Pharmaceuticals does not currently pay a dividend. Receive a free world-class investing education from MarketBeat. Winifred Gerald - March 18, 2021. Find out now with a free analysis on BioCryst Pharmaceuticals. The stock lies in the middle of a wide and strong rising trend in the short … BioCryst Pharmaceuticals has received 437 “outperform” votes. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy." According to 10 analysts, the average rating for BCRX stock is "Buy." Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. shlobby. shlobby. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Mar 11, 2021. Forecast Cash Runway: BCRX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24.6% each year. Should I buy or sell BCRX stock? Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. Our Accessibility Statement 8 of the analysts rate the stock as a “Buy”. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Pinterest . In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%. BCRX stock brief. If I had to chose one stock to own this next year you are looking at it. WhatsApp. Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. View real-time stock prices and stock quotes for a full financial overview. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. BioCryst Pharmaceuticals has a market capitalization of $2.35 billion and generates $48.83 million in revenue each year. Increased. 100% Free, Limited Time Only! MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. BioCryst Pharmaceuticals employs 140 workers across the globe. BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Learn everything you need to know about successful options trading with this three-part video course. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. WhatsApp. All rights reserved. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 BioCryst Pharmaceuticals, Inc. NASDAQ Updated Mar 16, 2021 11:59 PM BCRX 13.01 0.47 (3.49%). Facebook. Post-Market 0.09 (0.69%) View our full suite of financial calendars and market data tables, all for free. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. If I had to chose one stock to own this next year you are looking at it. (Add your “underperform” vote.). Since then, BCRX shares have increased by 411.2% and is now trading at $13.24. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. View which stocks are hot on social media with MarketBeat's trending stocks report. A Warner Media Company. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. Please log in to your account or sign up in order to add this asset to your watchlist. P/E  -11.6x. BioCryst Pharmaceuticals has a P/B Ratio of 50.92. ), BioCryst Pharmaceuticals has received 408 “underperform” votes. 3M 12M Bollinger Which way will BCRX go? P/B  -115.86x. Chart is setting up perfectly for 3/22 Data readout. Only 4.30% of the stock of BioCryst Pharmaceuticals is held by insiders. Top authors: BCRX. Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II. CNN Sans™ & © 2016 Cable News Network. Learn more. According to analysts' consensus price target of $11.78, BioCryst Pharmaceuticals has a forecasted downside of 11.0% from its current price of $13.24. Trend. To see all exchange delays and terms of use please see disclaimer. 2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. Their forecasts range from $6.00 to $16.00. You may vote once every thirty days. BCRX stock forecast for the next 10 days by pretiming. Long since 1.90's. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The high price target for BCRX is $16.00 and the low price target for BCRX is $6.00. High Growth Revenue: BCRX's revenue (42.4% per year) is forecast to grow faster than 20% per year. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how BCRX will perform in the near future. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Wednesday, February, 24th. sentiment. Disclaimer. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. 12, 2021. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between … The BioCryst Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. During that period the price should oscillate between … Pinterest. Detailed Estimate. BCRX Price  $12.64. Learn about financial terms, types of investments, trading strategies and more. 8 of the analysts rate the stock as a “Buy”. BCRX stock price history chart Price target for BioCryst Pharmaceuticals stock. BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. BCRX Stock Predictions. As of 2021 March 17, … BCRX Blogger Predictions > Hedge Fund Activity . Find real-time BXRX - Baudax Bio Inc stock quotes, company profile, news and forecasts from CNN Business. Strong Buy: Upgrades: $7.00-42.00%: 2020-05-05: Liisa Bayko. BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Get the latest Detailed Estimate from Zacks Investment Research. Fair Value Price. 8 of the analysts rate the stock as a “Buy”.
bcrx stock forecast 2021